Clinical Trials · NCT02235961
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 163
- Start date
- Sep 2014
- Locations
- 1 site, United States
- Primary endpoint
- Number of treatment emergent adverse events recorded